Document is current
Any future updates will be listed below
-
Authors
Munoz-Valencia, Alejandro
Aridi, Jackline O.
Barnes, Linda S.
Rudd, Kristina E.
Bidanda, Bopaya
Epuu, Tonny
Kamu, Robert
Kivuli, Tecla
Macleod, Jana
Makanga, Cindy M.
Makin, Jennifer
Mate, Muthoni
Muiru, Carolyne Njoki
Murithi, Gatwiri
Musa, Abdirahaman
Nyagol, Hellen
Ochieng, Kevin
Rajgopal, Jayant
Raykar, Nakul P.
Tian, Yiqi
Yazer, Mark H.
Zeng, Bo
Olayo, Bernard
Kumar, Pratap https://orcid.org/0000-0002-9807-3579
Puyana, Juan Carlos
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (1UG3HL151595-01)
- License Information
-
More Information
Article History
Received: 16 April 2022
Accepted: 17 August 2023
First Online: 7 September 2023
Declarations
:
: This study protocol was reviewed and approved by the Strathmore University Institutional Ethic Review Committee (reference number #SU-IERC0992/21), the Kenyan National Commission for Science, Technology & Innovation, and the University of Pittsburgh Institutional Review Board (reference number #STUDY21020040).Informed consent forms (ICFs) were included in the protocol for each participant category – patient, donor, clinician, blood bank administrator, health facility administrator and health system administrator. ICFs for patients and donors were translated into Swahili, Luo and Turkana languages.
: Not applicable.
: PK is a director in Health-E-Net Limited, which has commercial interests in the PaperEMR technology described in the manuscript. LSB is a consultant to the blood and biotherapies sector including the Association for the Advancement of Blood and Biotherapies (AABB). None of the opinions or views expressed in this manuscript obligate, bind, or otherwise commit the AABB. No commercial interests are reported for this manuscript. KER declares consulting fees from Janssen Pharmaceuticals unrelated to the scope of this manuscript. All other authors have no competing interests.
